UK markets close in 7 hours 11 minutes
  • FTSE 100

    7,533.30
    -2.76 (-0.04%)
     
  • FTSE 250

    20,282.28
    -54.13 (-0.27%)
     
  • AIM

    930.37
    -1.17 (-0.13%)
     
  • GBP/EUR

    1.1891
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2091
    -0.0004 (-0.03%)
     
  • BTC-GBP

    19,713.03
    -253.22 (-1.27%)
     
  • CMC Crypto 200

    568.99
    -2.92 (-0.51%)
     
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • DOW

    34,152.01
    +239.61 (+0.71%)
     
  • CRUDE OIL

    86.19
    -0.34 (-0.39%)
     
  • GOLD FUTURES

    1,786.60
    -3.10 (-0.17%)
     
  • NIKKEI 225

    29,222.77
    +353.86 (+1.23%)
     
  • HANG SENG

    19,918.12
    +87.60 (+0.44%)
     
  • DAX

    13,875.72
    -34.40 (-0.25%)
     
  • CAC 40

    6,583.42
    -9.16 (-0.14%)
     

Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux

·9-min read

PARIS, July 04, 2022--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:

- 448,434 shares
- € 33,899.60

- Number of executions on buy side on semester: 255
- Number of executions on sell side on semester: 222
- Traded volume on buy side on semester: 269,935 shares for € 99,624.74
- Traded volume on sell side on semester: 251,351 shares for € 96,727.03

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2021 on the liquidity account:

- 429,850 shares
- € 36,891.92

- Number of executions on buy side on semester: 256
- Number of executions on sell side on semester: 155
- Traded volume on buy side on semester: 357,510 shares for € 179,383.26
- Traded volume on sell side on semester: 221,580 shares for € 115,071.34

• the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe in combination with other treatment modalities in difficult-to-treat solid tumors.

OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).

APPENDIX

Buy Side

Sell Side

Number of
executions

Number of
shares

Traded volume
in EUR

Number of
executions

Number of
shares

Traded volume
in EUR

Total

255

269,935

99,624.74

222

251,351

96,727.03

03/01/2022

-

-

-

2

10,000

4,400.00

04/01/2022

3

5,000

2,200.00

1

5,000

2,250.00

05/01/2022

2

5,000

2,150.00

-

-

-

06/01/2022

2

5,000

2,100.00

-

-

-

07/01/2022

-

-

-

14

7,267

3,124.81

10/01/2022

2

4,193

1,761.06

-

-

-

11/01/2022

6

5,807

2,497.01

3

12,733

5,602.52

12/01/2022

1

4,645

1,997.35

-

-

-

13/01/2022

3

7,786

3,347.98

1

5,000

2,200.00

17/01/2022

1

2,569

1,078.98

-

-

-

20/01/2022

1

5,000

2,050.00

-

-

-

24/01/2022

3

5,000

2,000.00

1

1

0.42

25/01/2022

-

-

-

2

5,000

2,050.00

28/01/2022

2

1,443

577.20

-

-

-

31/01/2022

1

1

0.40

2

2,894

1,215.48

01/02/2022

1

3,556

1,422.40

-

-

-

03/02/2022

-

-

-

1

2,133

874.53

09/02/2022

3

625

243.75

-

-

-

10/02/2022

6

4,376

1,706.64

1

1

0.40

11/02/2022

1

1

0.40

1

1

0.40

16/02/2022

1

1

0.40

1

1

0.40

21/02/2022

4

10,000

3,800.00

1

1

0.38

22/02/2022

4

5,000

1,800.00

5

1,529

565.73

23/02/2022

-

-

-

10

3,471

1,284.27

24/02/2022

13

15,235

5,332.25

-

-

-

25/02/2022

2

4,765

1,572.45

9

6,071

2,064.14

28/02/2022

-

-

-

7

8,929

3,125.15

01/03/2022

3

2,410

819.40

8

25,000

9,250.00

02/03/2022

4

4,362

1,570.32

2

301

114.38

03/03/2022

-

-

-

1

1

0.38

04/03/2022

10

18,475

6,281.50

-

-

-

07/03/2022

13

15,000

4,800.00

-

-

-

08/03/2022

-

-

-

2

5,000

1,650.00

09/03/2022

-

-

-

7

18,860

6,789.60

11/03/2022

1

5,000

1,700.00

-

-

-

15/03/2022

1

1

0.35

2

2,001

720.36

16/03/2022

1

1

0.35

1

2,000

740.00

17/03/2022

2

2,001

720.36

1

1

0.36

18/03/2022

4

2,122

742.70

2

2,000

740.00

22/03/2022

-

-

-

4

2,000

740.00

23/03/2022

3

2,001

720.36

1

1

0.37

24/03/2022

7

2,001

720.36

5

2,001

720.36

28/03/2022

2

555

194.25

3

2,000

720.00

29/03/2022

4

2,000

720.00

1

100

37.00

30/03/2022

2

180

63.00

-

-

-

31/03/2022

1

1,265

442.75

5

2,001

740.37

01/04/2022

-

-

-

20

29,899

11,959.60

04/04/2022

2

930

372.00

2

4,000

1,720.00

05/04/2022

-

-

-

4

4,000

1,720.00

06/04/2022

3

4,000

1,720.00

6

8,000

3,440.00

07/04/2022

3

4,000

1,640.00

4

3,842

1,652.06

08/04/2022

6

8,000

3,360.00

-

-

-

11/04/2022

-

-

-

1

2,000

840.00

12/04/2022

1

1

0.41

1

1

0.41

13/04/2022

4

6,615

2,579.85

3

2,000

800.00

14/04/2022

4

6,000

2,280.00

-

-

-

19/04/2022

1

2,000

760.00

1

2,000

780.00

20/04/2022

3

2,000

760.00

3

6,000

2,340.00

22/04/2022

1

1

0.39

4

2,838

1,135.20

25/04/2022

3

2,000

780.00

-

-

-

26/04/2022

2

127

49.53

2

1,164

465.60

27/04/2022

3

3,875

1,511.25

1

1

0.39

28/04/2022

5

2,001

760.38

1

1

0.38

29/04/2022

2

1,881

695.97

-

-

-

02/05/2022

3

2,120

784.40

2

401

152.38

03/05/2022

-

-

-

2

445

169.10

04/05/2022

2

2,001

720.36

1

1

0.38

05/05/2022

7

5,999

2,099.65

-

-

-

06/05/2022

2

780

273.00

4

4,000

1,440.00

09/05/2022

3

3,220

1,127.00

-

-

-

10/05/2022

1

800

280.00

2

4,000

1,440.00

11/05/2022

-

-

-

5

4,000

1,440.00

12/05/2022

3

3,200

1,120.00

-

-

-

16/05/2022

2

4,000

1,360.00

-

-

-

17/05/2022

-

-

-

2

2,000

700.00

18/05/2022

3

4,000

1,360.00

-

-

-

23/05/2022

-

-

-

1

2,000

700.00

24/05/2022

1

1

0.34

2

2,001

700.35

25/05/2022

6

2,000

680.00

1

1,000

350.00

27/05/2022

1

1

0.34

1

1

0.34

30/05/2022

1

35

11.90

1

2,000

700.00

31/05/2022

1

1

0.35

1

1

0.35

01/06/2022

6

3,965

1,387.75

1

1

0.36

02/06/2022

2

81

28.35

5

2,000

720.00

03/06/2022

1

523

183.05

-

-

-

06/06/2022

1

1

0.35

-

-

-

07/06/2022

1

1

0.36

5

2,029

730.44

08/06/2022

2

3,396

1,188.60

-

-

-

09/06/2022

1

2,000

680.00

-

-

-

10/06/2022

-

-

-

1

1

0.35

13/06/2022

3

2,000

680.00

1

1,999

699.65

14/06/2022

6

4,127

1,444.45

-

-

-

15/06/2022

8

11,873

3,918.09

2

3,767

1,243.11

16/06/2022

3

3,199

1,023.68

2

3,500

1,155.00

17/06/2022

1

801

248.31

4

1,157

381.81

20/06/2022

1

120

38.40

4

4,000

1,320.00

21/06/2022

2

3,880

1,241.60

-

-

-

22/06/2022

1

1

0.33

1

1

0.33

23/06/2022

-

-

-

4

6,000

2,040.00

24/06/2022

3

2,251

742.83

4

3,272

1,112.48

27/06/2022

3

1,284

436.56

3

2,729

955.15

28/06/2022

6

2,716

923.44

-

-

-

29/06/2022

3

753

248.49

-

-

-

30/06/2022

2

2,997

989.01

-

-

-

View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005354/en/

Contacts

Onxeo
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations
Arthur Rouillé
NewCap
onxeo@newcap.eu
+33 1 44 71 94 98

Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92

Certified Adviser for Nasdaq First North
Kapital Partner
www.kapitalpartner.dk
info@kapitalpartner.dk
+45 89 88 78 46

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting